Naureen Quibria
Stock Analyst at Capital One
(0)
# 5034
Out of 5,243 analysts
15
Total ratings
9.09%
Success rate
-41.09%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Biomea Fusion | Initiates Coverage On: Overweight | 25 | 4.04 | 518.81% | 1 | Aug 29, 2024 | |
Immutep | Initiates Coverage On: Overweight | 10 | 1.93 | 418.13% | 1 | May 17, 2024 | |
Erasca | Initiates Coverage On: Overweight | 8 | 1.96 | 308.16% | 1 | Mar 11, 2024 | |
CARISMA Therapeutics | Initiates Coverage On: Overweight | 10 | 0.45 | 2122.22% | 1 | Oct 3, 2023 | |
Immunocore Hldgs | Initiates Coverage On: Overweight | 84 | 29.35 | 186.2% | 1 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 2 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 40 | 11.71 | 241.59% | 1 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 11 | 5.66 | 94.35% | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 7 | 3.42 | 104.68% | 2 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 21 | 4.13 | 408.47% | 1 | Jan 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 22 | n/a | n/a | 1 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 180 | 1.49 | 11980.54% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 35 | n/a | n/a | 1 | Mar 16, 2021 |